PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Get Free Report) insider Deepika Jalota sold 33,065 shares of the firm's stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $1.06, for a total value of $35,048.90. Following the sale, the insider directly owned 89,959 shares of the company's stock, valued at approximately $95,356.54. This trade represents a 26.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
PMV Pharmaceuticals Stock Up 10.0%
Shares of PMVP traded up $0.11 on Friday, reaching $1.21. The stock had a trading volume of 582,828 shares, compared to its average volume of 197,220. The firm has a market capitalization of $62.86 million, a PE ratio of -1.03 and a beta of 1.49. The firm has a 50-day moving average of $0.99 and a 200 day moving average of $1.18. PMV Pharmaceuticals, Inc. has a twelve month low of $0.81 and a twelve month high of $1.82.
PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report) last announced its earnings results on Friday, May 9th. The company reported ($0.34) EPS for the quarter, beating analysts' consensus estimates of ($0.37) by $0.03. On average, sell-side analysts anticipate that PMV Pharmaceuticals, Inc. will post -1.06 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Separately, HC Wainwright reissued a "buy" rating and issued a $5.00 target price on shares of PMV Pharmaceuticals in a report on Thursday, March 20th.
Check Out Our Latest Analysis on PMVP
Institutional Investors Weigh In On PMV Pharmaceuticals
Institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its stake in shares of PMV Pharmaceuticals by 2,282.8% during the fourth quarter. JPMorgan Chase & Co. now owns 24,591 shares of the company's stock worth $37,000 after purchasing an additional 23,559 shares in the last quarter. Velan Capital Investment Management LP purchased a new position in PMV Pharmaceuticals in the fourth quarter valued at about $53,000. Squarepoint Ops LLC boosted its holdings in PMV Pharmaceuticals by 68.7% in the fourth quarter. Squarepoint Ops LLC now owns 73,015 shares of the company's stock valued at $110,000 after purchasing an additional 29,722 shares during the last quarter. Northern Trust Corp boosted its holdings in PMV Pharmaceuticals by 23.2% in the fourth quarter. Northern Trust Corp now owns 107,340 shares of the company's stock valued at $162,000 after purchasing an additional 20,190 shares during the last quarter. Finally, Bridgeway Capital Management LLC boosted its holdings in PMV Pharmaceuticals by 44.5% in the fourth quarter. Bridgeway Capital Management LLC now owns 202,100 shares of the company's stock valued at $305,000 after purchasing an additional 62,200 shares during the last quarter. Hedge funds and other institutional investors own 90.20% of the company's stock.
About PMV Pharmaceuticals
(
Get Free Report)
PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.
Recommended Stories
Before you consider PMV Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PMV Pharmaceuticals wasn't on the list.
While PMV Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.